Biomerica (BMRA) Competitors $3.61 +0.01 (+0.28%) Closing price 04:00 PM EasternExtended Trading$3.63 +0.02 (+0.58%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRA vs. TRDA, ARCT, TSHA, HRTX, ATYR, ATAI, PVLA, AURA, CYRX, and GLUEShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Entrada Therapeutics (TRDA), Arcturus Therapeutics (ARCT), Taysha Gene Therapies (TSHA), Heron Therapeutics (HRTX), Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), Palvella Therapeutics (PVLA), Aura Biosciences (AURA), Cryoport (CYRX), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Entrada Therapeutics Arcturus Therapeutics Taysha Gene Therapies Heron Therapeutics Atyr PHARMA Atai Life Sciences Palvella Therapeutics Aura Biosciences Cryoport Monte Rosa Therapeutics Biomerica (NASDAQ:BMRA) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability. Which has better valuation & earnings, BMRA or TRDA? Biomerica has higher earnings, but lower revenue than Entrada Therapeutics. Biomerica is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomerica$5.68M1.64-$5.98M-$2.32-1.58Entrada Therapeutics$210.78M1.65-$6.68M$1.914.80 Is BMRA or TRDA more profitable? Entrada Therapeutics has a net margin of 25.53% compared to Biomerica's net margin of -100.52%. Entrada Therapeutics' return on equity of 16.11% beat Biomerica's return on equity.Company Net Margins Return on Equity Return on Assets Biomerica-100.52% -90.19% -64.54% Entrada Therapeutics 25.53%16.11%10.39% Do insiders & institutionals have more ownership in BMRA or TRDA? 22.3% of Biomerica shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 15.0% of Biomerica shares are owned by insiders. Comparatively, 7.6% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate BMRA or TRDA? Entrada Therapeutics has a consensus price target of $25.67, suggesting a potential upside of 180.05%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the MarketBeat Community prefer BMRA or TRDA? Biomerica received 116 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 84.00% of users gave Entrada Therapeutics an outperform vote while only 67.82% of users gave Biomerica an outperform vote. CompanyUnderperformOutperformBiomericaOutperform Votes13767.82% Underperform Votes6532.18% Entrada TherapeuticsOutperform Votes2184.00% Underperform Votes416.00% Does the media refer more to BMRA or TRDA? In the previous week, Entrada Therapeutics had 2 more articles in the media than Biomerica. MarketBeat recorded 4 mentions for Entrada Therapeutics and 2 mentions for Biomerica. Biomerica's average media sentiment score of 0.96 beat Entrada Therapeutics' score of 0.53 indicating that Biomerica is being referred to more favorably in the media. Company Overall Sentiment Biomerica Positive Entrada Therapeutics Positive Which has more volatility and risk, BMRA or TRDA? Biomerica has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500. SummaryEntrada Therapeutics beats Biomerica on 14 of the 19 factors compared between the two stocks. Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.32M$2.64B$5.54B$7.99BDividend YieldN/A0.75%5.09%4.22%P/E Ratio-10.767.8822.6818.71Price / Sales1.6449.47405.96105.45Price / CashN/A15.7538.1834.62Price / Book9.383.836.844.31Net Income-$5.98M-$65.73M$3.22B$248.10M7 Day Performance-5.67%1.28%1.84%2.02%1 Month Performance-19.55%-3.16%3.19%3.60%1 Year Performance-23.75%-10.89%16.30%5.11% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomerica1.2749 of 5 stars$3.61+0.3%N/A-28.6%$9.19M$5.68M-10.6260TRDAEntrada Therapeutics3.0006 of 5 stars$7.95-2.2%$25.67+222.9%-31.7%$298.88M$210.78M5.00110Upcoming EarningsNews CoverageHigh Trading VolumeARCTArcturus Therapeutics3.1267 of 5 stars$11.00+4.5%$59.20+438.2%-55.2%$298.32M$138.39M-4.95180News CoveragePositive NewsTSHATaysha Gene Therapies1.9764 of 5 stars$1.45+16.9%$6.63+356.9%-0.4%$297.33M$8.33M2.30180News CoverageGap UpHRTXHeron Therapeutics3.6214 of 5 stars$1.93+4.9%$5.67+193.6%+0.4%$294.00M$144.29M-10.72300Upcoming EarningsATYRAtyr PHARMA2.5822 of 5 stars$3.28+5.8%$18.60+467.1%N/A$291.46M$235,000.00-3.4953Short Interest ↑Analyst RevisionNews CoverageGap UpATAIAtai Life Sciences2.6885 of 5 stars$1.42-3.4%$10.50+639.4%-28.3%$283.69M$308,000.00-1.7580PVLAPalvella Therapeutics3.448 of 5 stars$25.45+4.5%$44.43+74.6%N/A$280.43M$42.81M-2.10N/AAnalyst ForecastHigh Trading VolumeAURAAura Biosciences2.1526 of 5 stars$5.57+3.9%$22.75+308.4%-20.7%$279.75MN/A-3.2250Upcoming EarningsShort Interest ↑News CoverageCYRXCryoport2.6534 of 5 stars$5.52-0.5%$11.67+111.4%-67.5%$275.50M$228.39M-1.631,020Upcoming EarningsNews CoveragePositive NewsGLUEMonte Rosa Therapeutics1.9678 of 5 stars$4.46-2.0%$15.50+247.5%-17.5%$274.34M$75.62M-2.4490Upcoming EarningsShort Interest ↑News Coverage Related Companies and Tools Related Companies Entrada Therapeutics Alternatives Arcturus Therapeutics Alternatives Taysha Gene Therapies Alternatives Heron Therapeutics Alternatives Atyr PHARMA Alternatives Atai Life Sciences Alternatives Palvella Therapeutics Alternatives Aura Biosciences Alternatives Cryoport Alternatives Monte Rosa Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BMRA Stock Free BMRA Stock Alerts